April 6, 2026 4:36pm

Inflation data, CPI, PCI, GDP, initial jobless claims, consumer credit, personal income and spending, durable goods and wholesale inventories reporting this week

Ceasefire deadline, I’m not sure will materialize; start thinking share pricing risk avoidance!

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

RMi Pre-opening: It ain’t over until the fat lady, Ms. Econ sings … https://www.regmedinvestors.com/articles/14371   

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

What happened and some of the whys with the numbers behind

… it’s NOT always about BUYs/SELLs … it’s about knowing when and what!

 

Monday: The Dow closed UP +163.70 points or +0.35%, the S&P closed UP +29.28 points or +0.44% while the Nasdaq closed UP +117.155 points or +0.54%

  • Theme of the session: oil prices seesawed. Brent crude futures (BZ=F) rose to around $109 per barrel, while West Texas Intermediate (WTI) futures (CL=F) gained more than 1% to trade at $112.

Monday’s (my) 40-company covered sector’s advance/decline line opened positive with 22 incliners, 14 decliners and 4 flats, ending with a positive close of 20 incliner, 18 decliners and 2 flats

  • Inter-mixed military operations and financial markets present an initial uncertain outcome

Henry’omics: We need to more than consider the economic/political environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • The ISM services index slipped to 54 for the month, down 2.1 points from February and below the consensus estimate for 55.4, but still above the 50-line between expansion and contraction.
  • Within the survey, there were several trouble points: The prices index spiked to 70.7, up 7.7 points to its highest since October 2022, while the employment index plunged 6.6 points to 45.2, its lowest since December 2023.
  • New orders overall edged higher to 60.6 though new export orders slumped 6.5 points to 50.7. Business activity fell 6 points to 53.9 while imports rose to 55.2, an increase of 3.4 points.

The CBOE Fear (VIX) index, Monday closed at 24.16, Friday was a market holiday, Thursday closed at 24.04, Wednesday’s 24.61, Tuesday’s 25.39 and last Monday’s 30.61

Metrics: Monday …

  • The RUT was up +10.60 points or +0.42%,
  • The XLV was down -0.53 points or -0.36%,
  • The NBI was down -25.79 points or -0.44%;
  • The XBI was down -0.16 points or -0.12%
  • The IWM was up +1.07 or +0.43%;
  • The IBB was down -0.60 points or -0.35%,
  • The VIX was up +0.29 points or +1.22% at to 24.16

 

Q2/26 – 1 holiday, 1 neutral and 2 positive closes

  • Q1 -March – 9 positive and 13 negative closes
  • February – 1 holiday, 8 negative and 11 positive sessions
  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

 

Monday Closing UP (10 of 20) Friday was a market holiday 

  • Alnylam Pharmaceuticals (ALNY +$11.49 after Thursday’s -$9.88),
  • Entrada Therapeutics (TRDA +$0.73 after Thursday’s -$0.33),
  • Agenus (AGEN +$0.44),
  • Ultragenyx Pharmaceuticals (RARE +$0.42 after Thursday’s +$1.03),
  • Regenxbio (RGNX +$0.27 after Thursday’s -$0.10)
  • Precigen (PGEN +$0.25),
  • Solid Biosciences (SLDB +$0.25),
  • uniQure NV QURE +$0.23),
  • Intellia Therapeutics (NTLA +$0.17 after Thursday’s -$0.14),
  • BioNTech (BNTX +$0.10 after Thursday’s +$1.76

Flat (2)

  • Brainstorm Cell Therapeutics (BCLI)
  • Generation Bio (GBIO) – acquired

Monday’s Closing DOWN (10 of 18): Friday was a market holiday    

  • Vertex (VRTX -$4.41 after Thursday’s -$8.55),
  • IQVIA Holdings (IQV -$2.59 after Thursday’s +$0.85),
  • AxoGen (AXGN -$1.80 after Thursday’s +$0.86),
  • DYNE Therapeutics (DYN -$0.49 after Thursday’s +$0.74),
  • Ionis Pharmaceuticals (IONS -$0.46 after Thursday’s -$0.34),
  • Moderna (MRNA -$0.43 after Thursday’s -$0.83),
  • Beam Therapeutics (BEAM -$0.43 after Thursday’s +$0.70),
  • Sarepta Therapeutics (SRPT -$0.43 after Thursday’s +$1.10),
  • Capricor Therapeutics (CAPR -$0.43 after Thursday’s +$1.99),
  • CRISPR Therapeutics (CRSP +$0.36),

 

The Bottom Line: More of the … WHY and a lot of what ifs …

There seems to be a big shift in the investing dynamic compared to the start of the year.

  • Keeping the fear quotient in mind, that will keep the fear bid in risk assets alive and thriving,

The 200-day moving average to be the "ultimate trendsetter" in financial markets.

  • It represents the average closing price of a stock or indexes over the past 200 trading days, effectively smoothing out daily "noise" to reveal the long-term trajectory.
  • When markets or a stock fall below this level, it's viewed as a major shift in investor sentiment.
  • In the current backdrop of volatile oil prices leading to uncertain outlooks for corporate profits, it's hard to see the immediate catalyst for the major indexes to climb back above the 200-day moving average. <Yahoo Finance>

The rest of the week worries me re share pricing!

 

April – 2nd week

  • 4/6 - Monday closed negative with 20 incliners, 18 decliners and 2 flats

April – 1st week

  • 4/2 - Thursday closed neutral with 19 incliners, 19 decliners and 2 flats
  • 4/1 – Wednesday closed positive with 29 incliners, 8 decliners and 3 flats

March – 5th week

  • 3/31 – Tuesday closed positive with 36 incliners, 2 decliners and 2 flats
  • 3/30 - Monday closed negative with 12 incliners, 26 decliners and 2 flats

March – 4th week:

  • 3/27 – Friday closed negative with 1 incliner, 36 decliners and 3 flats
  • 3/26 – Thursday closed negative with 15 incliner, 22 decliners and 3 flats
  • 3/25 – Wednesday closed positive with 30 incliners, 5 decliners and 5 flats
  • 3/24 – Tuesday closed negative with 11 incliner, 27 decliners and 2 flats
  • 3/23 - Monday closed positive with 26 incliners, 12 decliners and 2 flats

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there – closed end funds” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Monday: Alnylam Pharmaceuticals (ALNY), Entrada Therapeutics (TRDA) and Agenus (AGEN)
  • Friday: markets closed
  • Last Thursday: Capricor Therapeutics (CAPR), BioNTech (BNTX) and Vericel (VCEL

The worst three (3) in the session: Losers

  • Monday: IQIA Holdings (IQV), AxoGen (AXGN) and Vertex (VRTX)
  • Friday: markets closed
  • Last Thursday: Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and Arrowhead Pharmaceuticals (ARWR)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.